Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited ... Phosphodiesterase type 5; PH: Pulmonary hypertension.

[105] This trial enrolled 405 PAH patients (a majority were WHO functional class II and III) and randomized them to placebo or tadalafil 2.5, 10, 20, or 40 mg daily for 16 weeks. Compared with ...

Keros Therapeutics has halted dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial ...

Of the 50 patients with isolated PAPVD, 47 underwent right heart catheterisation (RHC), mean values: mean pulmonary arterial pressure (mPAP) 36.5 (±15) mmHg, pulmonary arterial wedge pressure (PAWP) ...

The company said the unanticipated events of pericardial effusion--when fluid builds up in the space around the heart--came in the Phase 2 clinical trial of 3 milligrams per kilogram and 4.6 mg/kg ...

A pooled analysis of two prior trials suggests patients with a variety of cardiac index scores saw improvement when Winrevair ...

The woman was suffering from Eisenmenger syndrome, a condition that occurs when a congenital heart defect causes abnormal blood circulation, resulting in pulmonary hypertension and lung damage. "As ...

Safety concerns Keros observed in a Phase 2 trial triggered a stock selloff for what had been one of the sector’s most successful initial public offerings of the last four years, according to ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer stability. Click for more on KROS.

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE ...